Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.
The company is particularly focused on the therapeutic potential of new peptide hormone drug candidates and the creation of novel and groundbreaking therapies for the treatment of diabetes, obesity, and other metabolic diseases.
Our vision at Amylin is shaped by two overarching goals that are inseparable: unleashing the potential of peptide and protein science to transform lives; and building a sustainable, profitable company that delivers superior shareholder value.
Science is our way of making a difference. It is not just science for the sake of science, but science in the interest of changing the balance between illness and health, between a limited life and a full one. It is why, at the end of the day, we can honestly say we are Challenging Science and Changing Lives.